ATR protein inhibitors - Pipeline Insight, 2022
This report can be delivered to the clients within 2-3 Business Days
DelveInsight’s, “ATR protein inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 9+ companies and 9+ pipeline drugs in ATR protein inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
ATR protein inhibitors: Overview
Serine/threonine-protein kinase ATR also known as ataxia telangiectasia and Rad3-related protein (ATR) or FRAP-related protein 1 (FRP1) is an enzyme that, in humans, is encoded by the ATR gene.It is a large kinase of about 301.66 kDa. ATR belongs to the phosphatidylinositol 3-kinase-related kinase protein family. ATR is activated in response to single strand breaks, and works with ATM to ensure genome integrity. ATR/ChK1 inhibitors can potentiate the effect of DNA cross-linking agents such as cisplatin and nucleoside analogues such as gemcitabine.The first clinical trials using inhibitors of ATR have been initiated by AstraZeneca, preferably in ATM-mutated chronic lymphocytic leukaemia (CLL), prolymphocytic leukaemia (PLL) or B-cell lymphoma patients and by Vertex Pharmaceuticals in advanced solid tumours. ATR provided and exciting point for potential targeting in these solid tumors, as many tumors function through activating the DNA damage response.
Report Highlights
This segment of the ATR protein inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
ATR protein inhibitors Emerging Drugs
Further product details are provided in the report……..
ATR protein inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different ATR protein inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
ATR protein inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses ATR protein inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging ATR protein inhibitors drugs.
ATR protein inhibitors Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “ATR protein inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 9+ companies and 9+ pipeline drugs in ATR protein inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
ATR protein inhibitors: Overview
Serine/threonine-protein kinase ATR also known as ataxia telangiectasia and Rad3-related protein (ATR) or FRAP-related protein 1 (FRP1) is an enzyme that, in humans, is encoded by the ATR gene.It is a large kinase of about 301.66 kDa. ATR belongs to the phosphatidylinositol 3-kinase-related kinase protein family. ATR is activated in response to single strand breaks, and works with ATM to ensure genome integrity. ATR/ChK1 inhibitors can potentiate the effect of DNA cross-linking agents such as cisplatin and nucleoside analogues such as gemcitabine.The first clinical trials using inhibitors of ATR have been initiated by AstraZeneca, preferably in ATM-mutated chronic lymphocytic leukaemia (CLL), prolymphocytic leukaemia (PLL) or B-cell lymphoma patients and by Vertex Pharmaceuticals in advanced solid tumours. ATR provided and exciting point for potential targeting in these solid tumors, as many tumors function through activating the DNA damage response.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence ATR protein inhibitors R&D. The therapies under development are focused on novel approaches for ATR protein inhibitors.
This segment of the ATR protein inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
ATR protein inhibitors Emerging Drugs
- Ceralasertib: AstraZeneca
- Elimusertib: Bayer
Further product details are provided in the report……..
ATR protein inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different ATR protein inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on ATR protein inhibitors
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
ATR protein inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses ATR protein inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging ATR protein inhibitors drugs.
ATR protein inhibitors Report Insights
- ATR protein inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing ATR protein inhibitors drugs?
- How many ATR protein inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of ATR protein inhibitors?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the ATR protein inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for ATR protein inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
- AstraZeneca
- Bayer
- Repare Therapeutics
- Merck KGaA
- Artios Pharma
- Cybrexa Therapeutics
- Antengene Corporation
- IMPACT Therapeutics
- Laevoroc Neuro-Oncology
- Vertex Pharmaceuticals
- Ceralasertib
- Elimusertib
- RP 3500
- Berzosertib
- ART 0380
- M 1774
- CBX-13
- ATG 018
- IMP 09
- LR 02
- VE 821
Introduction
Executive Summary
ATR protein inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
ATR protein inhibitors – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Ceralasertib: AstraZeneca
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Elimusertib: Bayer
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
ATG 018: Antengene Corporation
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
ATR protein inhibitors Key Companies
ATR protein inhibitors Key Products
ATR protein inhibitors- Unmet Needs
ATR protein inhibitors- Market Drivers and Barriers
ATR protein inhibitors- Future Perspectives and Conclusion
ATR protein inhibitors Analyst Views
ATR protein inhibitors Key Companies
Appendix
Executive Summary
ATR protein inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
ATR protein inhibitors – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Ceralasertib: AstraZeneca
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Elimusertib: Bayer
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
ATG 018: Antengene Corporation
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
ATR protein inhibitors Key Companies
ATR protein inhibitors Key Products
ATR protein inhibitors- Unmet Needs
ATR protein inhibitors- Market Drivers and Barriers
ATR protein inhibitors- Future Perspectives and Conclusion
ATR protein inhibitors Analyst Views
ATR protein inhibitors Key Companies
Appendix